News & Media

Purdue is at the forefront of medical advances and provides timely news updates about its family of products, resources, and events.

PrintFont Size

Recent News

Welcome to the Purdue Newsroom

In this section you will find recent news and events pertaining to Purdue, products, and programs.

Purdue Pharma L.P. Announces Positive Phase 3 Clinical Trial Results of Once-Daily Hydrocodone Bitartrate Extended-Release Tablets


Purdue Pharma L.P. Names Mark Timney President and Chief Executive Officer


Purdue Pharma L.P. Announces Resolution of OxyContin® (oxycodone HCl controlled-release) Tablets CII Patent Lawsuit with Impax Laboratories, Inc.


FDA Accepts for Review Purdue Pharma’s New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCL Controlled-Release) Tablets CII


Purdue Pharma L.P. Receives FDA Approval For 15 Mcg/Hour Dosage Strength Of Butrans® (Buprenorphine) Transdermal System CIII


RxSafetyMatters Receives 2013 Communicator Award for its Mobile Site


New Teacher Guide to Prevent Prescription Drug Abuse by High Schoolers


Purdue Pharma L.P. To Present Data Describing Changes In Oxycodone Abuse In Rural Kentucky Following The Introduction Of Reformulated Oxycontin® (Oxycodone HCl Controlled-Release) At The College On Problems Of Drug Dependence 2013 Annual Meeting


Purdue Pharma L.P. To Present Data Regarding Long-Term Opioid Therapy At American Pain Society Annual Meeting


Purdue Pharma L.P. Announces Resolution of OxyContin® (oxycodone HCl controlled-release) Tablets CII Patent Lawsuit with Actavis, Inc.


Purdue Pharma L.P. Statement on FDA Approval of New Label for Reformulated OxyContin® (oxycodone HCL controlled-release) Tablets CII and FDA Decision Regarding Withdrawal of Original Formulation Due to Safety


Want to go on a Shopping Spree?


ElMindA and Purdue Pharma L.P. Enter Research Agreement to Develop Novel Diagnostics to Improve Pain Management


Four Cities Win Grants For Outstanding Prescription Drug Abuse Prevention Initiatives


National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season


NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to support State Prescription Drug Monitoring Programs


Albuquerque Mayor Richard Berry Launches Public Education Campaign to Combat Prescription Medication Abuse Through Safe Storage and Disposal


Purdue Pharma L.P. Comments on FDA Announcement On REMS For Extended-Release And Long-Acting Opioid Analgesics


Partnership Aims to Prevent Students from Misusing Prescription Drugs


Purdue Pharma L.P. to Present Data on Physician Understanding of the Risk Evaluation and Mitigation Strategy (REMS) For Butrans® (buprenorphine) Transdermal System CIII Data at International Society of Pharmacoeconomics and Outcomes Research Annual Meeting


Purdue Pharma L.P. to Present Analysis of Butrans® (buprenorphine) Transdermal System CIII Clinical Data at American Pain Society Annual Meeting


New Educational Resource Helps Healthcare Professionals Recognize, Address Substance Abuse in Clinical Practice Settings


Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV Are Now Available for Insomnia Characterized by Middle-of-the-Night Awakenings Followed by Difficulty Returning to Sleep


close  x

Email to a Friend or Colleague

Thank you! The page has been sent.

There was a problem sending this page, please try again.

Enter your email address and your friend’s email address,
then click the Send button.

*Indicates a required field

Sender’s email:*

Recipient’s email:*

Message: (max 500 characters)

No personal information including e-mail addresses about you or the recipient will be collected from this email notification feature offered by Purdue Pharma, L.P.

close  x